{"transactions":[{"id":915848,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":67397,"kind":"person","name":"Podlesak Dennis","position":1,"cik":"0001314595","reported_name":"Podlesak Dennis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-06T16:14:08.000Z","date":"2026-02-04","kind":"grant","planned":false,"acquired":true,"shares":48000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control."}],"balance_after":239763,"source":{"system":"sec-edgar","filing":"0001193125-26-041200","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314595/000119312526041200/ownership.xml","form_type":"4"}},{"id":1063656,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":67397,"kind":"person","name":"Podlesak Dennis","position":1,"cik":"0001314595","reported_name":"Podlesak Dennis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2025-08-18T17:02:20.000Z","date":"2025-08-18","kind":"exercise","planned":true,"acquired":false,"shares":19200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":7.2,"expiration_date":"2025-08-20","underlying":"Common Stock","underlying_shares":19200},"source":{"system":"sec-edgar","filing":"0000950170-25-109815","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1314595/000095017025109815/ownership.xml","form_type":"4"}},{"id":1063655,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":67397,"kind":"person","name":"Podlesak Dennis","position":1,"cik":"0001314595","reported_name":"Podlesak Dennis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2025-08-18T17:02:20.000Z","date":"2025-08-15","kind":"exercise","planned":true,"acquired":false,"shares":4800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":7.2,"expiration_date":"2025-08-20","underlying":"Common Stock","underlying_shares":4800},"source":{"system":"sec-edgar","filing":"0000950170-25-109815","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1314595/000095017025109815/ownership.xml","form_type":"4"}},{"id":1063654,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":67397,"kind":"person","name":"Podlesak Dennis","position":1,"cik":"0001314595","reported_name":"Podlesak Dennis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2025-08-18T17:02:20.000Z","date":"2025-08-15","kind":"exercise","planned":true,"acquired":false,"shares":14400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":7.2,"expiration_date":"2025-08-18","underlying":"Common Stock","underlying_shares":14400},"source":{"system":"sec-edgar","filing":"0000950170-25-109815","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1314595/000095017025109815/ownership.xml","form_type":"4"}},{"id":1063653,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":67397,"kind":"person","name":"Podlesak Dennis","position":1,"cik":"0001314595","reported_name":"Podlesak Dennis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2025-08-18T17:02:20.000Z","date":"2025-08-14","kind":"exercise","planned":true,"acquired":false,"shares":19200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":7.2,"expiration_date":"2025-08-18","underlying":"Common Stock","underlying_shares":19200},"source":{"system":"sec-edgar","filing":"0000950170-25-109815","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1314595/000095017025109815/ownership.xml","form_type":"4"}},{"id":1063652,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":67397,"kind":"person","name":"Podlesak Dennis","position":1,"cik":"0001314595","reported_name":"Podlesak Dennis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-08-18T17:02:20.000Z","date":"2025-08-18","kind":"sale","planned":true,"acquired":false,"shares":19200,"price":15.8422,"value":304170.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person solely covering equity grants with expiration dates prior to August 21, 2025. Following the sales reported in this Form 4, the Reporting Person has a total of 135,000 options to purchase shares of common stock that are vested and immediately exercisable and no unvested options to purchase shares of common stock."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The sale prices ranged from $15.61 to $16.00."}],"balance_after":191763,"source":{"system":"sec-edgar","filing":"0000950170-25-109815","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1314595/000095017025109815/ownership.xml","form_type":"4"}},{"id":1063651,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":67397,"kind":"person","name":"Podlesak Dennis","position":1,"cik":"0001314595","reported_name":"Podlesak Dennis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-08-18T17:02:20.000Z","date":"2025-08-18","kind":"exercise","planned":true,"acquired":true,"shares":19200,"price":7.2,"value":138240.0,"ownership":{"direct":true},"balance_after":210963,"source":{"system":"sec-edgar","filing":"0000950170-25-109815","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1314595/000095017025109815/ownership.xml","form_type":"4"}},{"id":1063650,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":67397,"kind":"person","name":"Podlesak Dennis","position":1,"cik":"0001314595","reported_name":"Podlesak Dennis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-08-18T17:02:20.000Z","date":"2025-08-15","kind":"sale","planned":true,"acquired":false,"shares":19200,"price":15.5421,"value":298408.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person solely covering equity grants with expiration dates prior to August 21, 2025. Following the sales reported in this Form 4, the Reporting Person has a total of 135,000 options to purchase shares of common stock that are vested and immediately exercisable and no unvested options to purchase shares of common stock."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The sale prices ranged from $14.88 to $15.91."}],"balance_after":191763,"source":{"system":"sec-edgar","filing":"0000950170-25-109815","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1314595/000095017025109815/ownership.xml","form_type":"4"}},{"id":1063649,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":67397,"kind":"person","name":"Podlesak Dennis","position":1,"cik":"0001314595","reported_name":"Podlesak Dennis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-08-18T17:02:20.000Z","date":"2025-08-15","kind":"exercise","planned":true,"acquired":true,"shares":19200,"price":7.2,"value":138240.0,"ownership":{"direct":true},"balance_after":210963,"source":{"system":"sec-edgar","filing":"0000950170-25-109815","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1314595/000095017025109815/ownership.xml","form_type":"4"}},{"id":1063648,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":67397,"kind":"person","name":"Podlesak Dennis","position":1,"cik":"0001314595","reported_name":"Podlesak Dennis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-08-18T17:02:20.000Z","date":"2025-08-14","kind":"sale","planned":true,"acquired":false,"shares":19200,"price":14.1938,"value":272520.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person solely covering equity grants with expiration dates prior to August 21, 2025. Following the sales reported in this Form 4, the Reporting Person has a total of 135,000 options to purchase shares of common stock that are vested and immediately exercisable and no unvested options to purchase shares of common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale prices ranged from $13.30 to $14.80."}],"balance_after":191763,"source":{"system":"sec-edgar","filing":"0000950170-25-109815","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1314595/000095017025109815/ownership.xml","form_type":"4"}},{"id":1063647,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":67397,"kind":"person","name":"Podlesak Dennis","position":1,"cik":"0001314595","reported_name":"Podlesak Dennis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-08-18T17:02:20.000Z","date":"2025-08-14","kind":"exercise","planned":true,"acquired":true,"shares":19200,"price":7.2,"value":138240.0,"ownership":{"direct":true},"balance_after":210963,"source":{"system":"sec-edgar","filing":"0000950170-25-109815","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314595/000095017025109815/ownership.xml","form_type":"4"}},{"id":1278524,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":67397,"kind":"person","name":"Podlesak Dennis","position":1,"cik":"0001314595","reported_name":"Podlesak Dennis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-07T16:41:27.000Z","date":"2025-02-05","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control."}],"balance_after":191763,"source":{"system":"sec-edgar","filing":"0000950170-25-016380","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314595/000095017025016380/ownership.xml","form_type":"4"}},{"id":1651352,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":67397,"kind":"person","name":"Podlesak Dennis","position":1,"cik":"0001314595","reported_name":"Podlesak Dennis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-02-09T16:04:02.000Z","date":"2024-02-07","kind":"grant","planned":false,"acquired":true,"shares":34000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control."}],"balance_after":141763,"source":{"system":"sec-edgar","filing":"0001562180-24-001215","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314595/000156218024001215/primarydocument.xml","form_type":"4"}},{"id":2032460,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":67397,"kind":"person","name":"Podlesak Dennis","position":1,"cik":"0001314595","reported_name":"Podlesak Dennis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-02-03T16:57:50.000Z","date":"2023-02-02","kind":"grant","acquired":true,"shares":32000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control."}],"balance_after":107763,"source":{"system":"sec-edgar","filing":"0001562180-23-000947","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314595/000156218023000947/primarydocument.xml","form_type":"4"}},{"id":2157129,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":67397,"kind":"person","name":"Podlesak Dennis","position":1,"cik":"0001314595","reported_name":"Podlesak Dennis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2022-09-16T17:34:10.000Z","date":"2022-09-16","kind":"exercise","acquired":false,"shares":5419,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":6.32,"expiration_date":"2024-09-15","underlying":"Common Stock","underlying_shares":5419},"source":{"system":"sec-edgar","filing":"0001562180-22-006705","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1314595/000156218022006705/primarydocument.xml","form_type":"4"}},{"id":2157128,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":67397,"kind":"person","name":"Podlesak Dennis","position":1,"cik":"0001314595","reported_name":"Podlesak Dennis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2022-09-16T17:34:10.000Z","date":"2022-09-16","kind":"exercise","acquired":false,"shares":6556,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":6.35,"expiration_date":"2024-12-18","underlying":"Common Stock","underlying_shares":6556},"source":{"system":"sec-edgar","filing":"0001562180-22-006705","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1314595/000156218022006705/primarydocument.xml","form_type":"4"}},{"id":2157127,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":67397,"kind":"person","name":"Podlesak Dennis","position":1,"cik":"0001314595","reported_name":"Podlesak Dennis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2022-09-16T17:34:10.000Z","date":"2022-09-15","kind":"exercise","acquired":false,"shares":66840,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":6.32,"expiration_date":"2024-09-15","underlying":"Common Stock","underlying_shares":66840},"source":{"system":"sec-edgar","filing":"0001562180-22-006705","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1314595/000156218022006705/primarydocument.xml","form_type":"4"}},{"id":2157126,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":67397,"kind":"person","name":"Podlesak Dennis","position":1,"cik":"0001314595","reported_name":"Podlesak Dennis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-16T17:34:10.000Z","date":"2022-09-16","kind":"sale","acquired":false,"shares":6556,"price":23.4327,"value":153624.7812,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 192,600 options to purchase shares of common stock that are vested and immediately exercisable and no unvested options to purchase shares of common stock."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The sale prices ranged from $22.96 to $24.07"}],"balance_after":75763,"source":{"system":"sec-edgar","filing":"0001562180-22-006705","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1314595/000156218022006705/primarydocument.xml","form_type":"4"}},{"id":2157125,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":67397,"kind":"person","name":"Podlesak Dennis","position":1,"cik":"0001314595","reported_name":"Podlesak Dennis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-16T17:34:10.000Z","date":"2022-09-16","kind":"exercise","acquired":true,"shares":6556,"price":6.35,"value":41630.6,"ownership":{"direct":true},"balance_after":82319,"source":{"system":"sec-edgar","filing":"0001562180-22-006705","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1314595/000156218022006705/primarydocument.xml","form_type":"4"}},{"id":2157124,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":67397,"kind":"person","name":"Podlesak Dennis","position":1,"cik":"0001314595","reported_name":"Podlesak Dennis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-16T17:34:10.000Z","date":"2022-09-16","kind":"sale","acquired":false,"shares":5419,"price":23.4327,"value":126981.8013,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 192,600 options to purchase shares of common stock that are vested and immediately exercisable and no unvested options to purchase shares of common stock."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The sale prices ranged from $22.96 to $24.07"}],"balance_after":75763,"source":{"system":"sec-edgar","filing":"0001562180-22-006705","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1314595/000156218022006705/primarydocument.xml","form_type":"4"}},{"id":2157123,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":67397,"kind":"person","name":"Podlesak Dennis","position":1,"cik":"0001314595","reported_name":"Podlesak Dennis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-16T17:34:10.000Z","date":"2022-09-16","kind":"exercise","acquired":true,"shares":5419,"price":6.32,"value":34248.08,"ownership":{"direct":true},"balance_after":81182,"source":{"system":"sec-edgar","filing":"0001562180-22-006705","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1314595/000156218022006705/primarydocument.xml","form_type":"4"}},{"id":2157122,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":67397,"kind":"person","name":"Podlesak Dennis","position":1,"cik":"0001314595","reported_name":"Podlesak Dennis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-16T17:34:10.000Z","date":"2022-09-15","kind":"sale","acquired":false,"shares":66840,"price":24.1978,"value":1617380.952,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 192,600 options to purchase shares of common stock that are vested and immediately exercisable and no unvested options to purchase shares of common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale prices ranged from $23.37 to $24.64"}],"balance_after":75763,"source":{"system":"sec-edgar","filing":"0001562180-22-006705","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1314595/000156218022006705/primarydocument.xml","form_type":"4"}},{"id":2157121,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":67397,"kind":"person","name":"Podlesak Dennis","position":1,"cik":"0001314595","reported_name":"Podlesak Dennis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-16T17:34:10.000Z","date":"2022-09-15","kind":"exercise","acquired":true,"shares":66840,"price":6.32,"value":422428.8,"ownership":{"direct":true},"balance_after":142603,"source":{"system":"sec-edgar","filing":"0001562180-22-006705","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314595/000156218022006705/primarydocument.xml","form_type":"4"}},{"id":2413195,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":67397,"kind":"person","name":"Podlesak Dennis","position":1,"cik":"0001314595","reported_name":"Podlesak Dennis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-02-03T17:30:57.000Z","date":"2022-02-02","kind":"grant","acquired":true,"shares":32000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control."}],"balance_after":75763,"source":{"system":"sec-edgar","filing":"0001562180-22-001076","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314595/000156218022001076/primarydocument.xml","form_type":"4"}},{"id":2546997,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":67397,"kind":"person","name":"Podlesak Dennis","position":1,"cik":"0001314595","reported_name":"Podlesak Dennis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-10-06T16:09:07.000Z","date":"2021-10-05","kind":"other","acquired":true,"shares":463,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of Common Stock of the Issuer received from One Palmer Square Associates VIII, L.L.C. through a pro-rata distribution for no consideration."}],"balance_after":43763,"source":{"system":"sec-edgar","filing":"0001562180-21-006357","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314595/000156218021006357/primarydocument.xml","form_type":"4"}},{"id":2741791,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":67397,"kind":"person","name":"Podlesak Dennis","position":1,"cik":"0001314595","reported_name":"Podlesak Dennis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-22T17:06:52.000Z","date":"2021-04-22","kind":"purchase","acquired":true,"shares":13967,"price":14.1102,"value":197077.1634,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The purchase prices ranged from $13.98 to $14.29."}],"balance_after":43300,"source":{"system":"sec-edgar","filing":"0001562180-21-002912","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314595/000156218021002912/primarydocument.xml","form_type":"4"}},{"id":2876432,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":67397,"kind":"person","name":"Podlesak Dennis","position":1,"cik":"0001314595","reported_name":"Podlesak Dennis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-05T16:18:44.000Z","date":"2021-02-03","kind":"grant","acquired":true,"shares":29333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units that vests one year from the date of grant.  The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control."}],"balance_after":29333,"source":{"system":"sec-edgar","filing":"0001562180-21-000930","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314595/000156218021000930/primarydocument.xml","form_type":"4"}},{"id":3270148,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":67397,"kind":"person","name":"Podlesak Dennis","position":1,"cik":"0001314595","reported_name":"Podlesak Dennis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-02-14T16:33:17.000Z","date":"2020-02-12","kind":"grant","acquired":true,"shares":44000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":44000,"derivative":{"exercise_price":9.47,"exercise_date":"2021-02-12","expiration_date":"2030-02-12","underlying":"Common Stock","underlying_shares":44000},"source":{"system":"sec-edgar","filing":"0001562180-20-001228","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314595/000156218020001228/primarydocument.xml","form_type":"4"}},{"id":3492423,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":67397,"kind":"person","name":"Podlesak Dennis","position":1,"cik":"0001314595","reported_name":"Podlesak Dennis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-12T09:00:52.000Z","date":"2019-06-10","kind":"grant","acquired":true,"shares":44000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":44000,"derivative":{"exercise_price":7.88,"exercise_date":"2020-06-10","expiration_date":"2029-06-10","underlying":"Common Stock","underlying_shares":44000},"source":{"system":"sec-edgar","filing":"0001562180-19-003492","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314595/000156218019003492/primarydocument.xml","form_type":"4"}},{"id":3536749,"issuer":{"id":155807,"kind":"organization","name":"Adynxx, Inc.","symbol":"ADYX"},"owners":[{"id":67397,"kind":"person","name":"Podlesak Dennis","position":1,"cik":"0001314595","reported_name":"Podlesak Dennis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-05-07T21:02:58.000Z","date":"2019-05-03","kind":"grant","acquired":true,"shares":55879,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares of common stock of the corporation then known as Adynxx, Inc. (\"Private Adynxx\") were converted into shares of the Issuer pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of October 11, 2018, by and among the Issuer, Embark Merger Sub, Inc. and Private Adynxx (the \"Merger Agreement\"). Pursuant to the terms of the Merger Agreement, each share of common stock was converted into 0.0359 shares of the Issuer's common stock, after reflecting a reverse stock split at a ratio of one new share for every six shares of common stock outstanding."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On December 16, 2016, Reporting Person was granted an option to purchase 1,556,529 shares of the common stock of Private Adynxx under Private Adynxx's Equity Incentive Plan at an exercise price of $0.11 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 55,879 shares of the Issuer's common stock at a per share exercise price of $3.06. Subject to Reporting Person's continued employment, 1/4th of the option vested and became exercisable on December 16, 2017 with the remainder vesting monthly thereafter for a total vesting period of 48 months. Upon a change of control of the Issuer, 100% of any unvested portion of the option will become fully vested and exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On December 16, 2016, Reporting Person was granted an option to purchase 1,556,529 shares of the common stock of Private Adynxx under Private Adynxx's Equity Incentive Plan at an exercise price of $0.11 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 55,879 shares of the Issuer's common stock at a per share exercise price of $3.06. Subject to Reporting Person's continued employment, 1/4th of the option vested and became exercisable on December 16, 2017 with the remainder vesting monthly thereafter for a total vesting period of 48 months. Upon a change of control of the Issuer, 100% of any unvested portion of the option will become fully vested and exercisable."}],"balance_after":55879,"derivative":{"exercise_price":3.06,"expiration_date":"2026-12-15","underlying":"Common Stock","underlying_shares":55879},"source":{"system":"sec-edgar","filing":"0001209191-19-028148","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1054274/000120919119028148/doc4.xml","form_type":"4"}},{"id":3536748,"issuer":{"id":155807,"kind":"organization","name":"Adynxx, Inc.","symbol":"ADYX"},"owners":[{"id":67397,"kind":"person","name":"Podlesak Dennis","position":1,"cik":"0001314595","reported_name":"Podlesak Dennis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-05-07T21:02:58.000Z","date":"2019-05-03","kind":"grant","acquired":true,"shares":396,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares of common stock of the corporation then known as Adynxx, Inc. (\"Private Adynxx\") were converted into shares of the Issuer pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of October 11, 2018, by and among the Issuer, Embark Merger Sub, Inc. and Private Adynxx (the \"Merger Agreement\"). Pursuant to the terms of the Merger Agreement, each share of common stock was converted into 0.0359 shares of the Issuer's common stock, after reflecting a reverse stock split at a ratio of one new share for every six shares of common stock outstanding."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On December 18, 2012, Reporting Person was granted an option to purchase 11,041 shares of the common stock of Private Adynxx under Private Adynxx's 2010 Equity Incentive Plan at an exercise price of $0.05 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 396 shares of the Issuer's common stock at a per share exercise price of $1.39. This option has fully vested."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On December 18, 2012, Reporting Person was granted an option to purchase 11,041 shares of the common stock of Private Adynxx under Private Adynxx's 2010 Equity Incentive Plan at an exercise price of $0.05 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 396 shares of the Issuer's common stock at a per share exercise price of $1.39. This option has fully vested."}],"balance_after":396,"derivative":{"exercise_price":1.39,"expiration_date":"2022-12-17","underlying":"Common Stock","underlying_shares":396},"source":{"system":"sec-edgar","filing":"0001209191-19-028148","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1054274/000120919119028148/doc4.xml","form_type":"4"}},{"id":3536747,"issuer":{"id":155807,"kind":"organization","name":"Adynxx, Inc.","symbol":"ADYX"},"owners":[{"id":67397,"kind":"person","name":"Podlesak Dennis","position":1,"cik":"0001314595","reported_name":"Podlesak Dennis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-07T21:02:58.000Z","date":"2019-05-03","kind":"grant","acquired":true,"shares":85254,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares of common stock of the corporation then known as Adynxx, Inc. (\"Private Adynxx\") were converted into shares of the Issuer pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of October 11, 2018, by and among the Issuer, Embark Merger Sub, Inc. and Private Adynxx (the \"Merger Agreement\"). Pursuant to the terms of the Merger Agreement, each share of common stock was converted into 0.0359 shares of the Issuer's common stock, after reflecting a reverse stock split at a ratio of one new share for every six shares of common stock outstanding."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares of common stock of the corporation then known as Adynxx, Inc. (\"Private Adynxx\") were converted into shares of the Issuer pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of October 11, 2018, by and among the Issuer, Embark Merger Sub, Inc. and Private Adynxx (the \"Merger Agreement\"). Pursuant to the terms of the Merger Agreement, each share of common stock was converted into 0.0359 shares of the Issuer's common stock, after reflecting a reverse stock split at a ratio of one new share for every six shares of common stock outstanding."}],"balance_after":85254,"source":{"system":"sec-edgar","filing":"0001209191-19-028148","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1054274/000120919119028148/doc4.xml","form_type":"4"}},{"id":3916789,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":67397,"kind":"person","name":"Podlesak Dennis","position":1,"cik":"0001314595","reported_name":"Podlesak Dennis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-05-25T08:59:51.000Z","date":"2018-05-23","kind":"grant","acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":14000,"derivative":{"exercise_price":8.93,"exercise_date":"2019-05-23","expiration_date":"2028-05-23","underlying":"Common Stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0001562180-18-002680","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314595/000156218018002680/primarydocument.xml","form_type":"4"}},{"id":4065748,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":67397,"kind":"person","name":"Podlesak Dennis","position":1,"cik":"0001314595","reported_name":"Podlesak Dennis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-02-12T16:01:12.000Z","date":"2018-02-08","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the shares subject to the option shall vest monthly over a three-year period."}],"balance_after":10000,"derivative":{"exercise_price":9.63,"expiration_date":"2028-02-08","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001562180-18-000723","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314595/000156218018000723/primarydocument.xml","form_type":"4"}},{"id":4311449,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":67397,"kind":"person","name":"Podlesak Dennis","position":1,"cik":"0001314595","reported_name":"Podlesak Dennis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-05-19T11:26:55.000Z","date":"2017-05-17","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the shares subject to the option shall vest monthly over a three-year period."}],"balance_after":5000,"derivative":{"exercise_price":13.58,"expiration_date":"2027-05-17","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001562180-17-002009","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1314595/000156218017002009/primarydocument.xml","form_type":"4"}},{"id":4311448,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":67397,"kind":"person","name":"Podlesak Dennis","position":1,"cik":"0001314595","reported_name":"Podlesak Dennis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-05-19T11:26:55.000Z","date":"2017-05-17","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":10000,"derivative":{"exercise_price":13.58,"exercise_date":"2018-05-17","expiration_date":"2027-05-17","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001562180-17-002009","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314595/000156218017002009/primarydocument.xml","form_type":"4"}},{"id":4567548,"issuer":{"id":181299,"kind":"organization","name":"Tobira Therapeutics, Inc.","symbol":"TBRA"},"owners":[{"id":67397,"kind":"person","name":"Podlesak Dennis","position":1,"cik":"0001314595","reported_name":"Podlesak Dennis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2016-11-03T14:27:02.000Z","date":"2016-11-01","kind":"disposition_to_issuer","acquired":false,"shares":17695,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. (\"Parent\") and Sapphire Acquisition Corp. (\"Purchaser\"), pursuant to which Purchaser was merged with and into Issuer (the \"Merger\"), each option to purchase shares (a \"Company Option\") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the \"Shares\") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the \"Closing Amount\") (each, an \"In the Money Option\"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the \"Effective Time\")"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an \"Out of the Money Option\"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement (\"CVR Agreement\") on or prior to the fifth anniversary of the Effective Time (each such date, a \"Valuation Point\"),"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. (\"Parent\") and Sapphire Acquisition Corp. (\"Purchaser\"), pursuant to which Purchaser was merged with and into Issuer (the \"Merger\"), each option to purchase shares (a \"Company Option\") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the \"Shares\") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the \"Closing Amount\") (each, an \"In the Money Option\"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the \"Effective Time\")"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an \"Out of the Money Option\"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement (\"CVR Agreement\") on or prior to the fifth anniversary of the Effective Time (each such date, a \"Valuation Point\"),"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Shares subject to this option were fully vested immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":8.19,"expiration_date":"2025-01-01","underlying":"Common Stock","underlying_shares":17695},"source":{"system":"sec-edgar","filing":"0001209191-16-148104","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1311596/000120919116148104/doc4.xml","form_type":"4"}},{"id":4567547,"issuer":{"id":181299,"kind":"organization","name":"Tobira Therapeutics, Inc.","symbol":"TBRA"},"owners":[{"id":67397,"kind":"person","name":"Podlesak Dennis","position":1,"cik":"0001314595","reported_name":"Podlesak Dennis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2016-11-03T14:27:02.000Z","date":"2016-11-01","kind":"disposition_to_issuer","acquired":false,"shares":2947,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. (\"Parent\") and Sapphire Acquisition Corp. (\"Purchaser\"), pursuant to which Purchaser was merged with and into Issuer (the \"Merger\"), each option to purchase shares (a \"Company Option\") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the \"Shares\") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the \"Closing Amount\") (each, an \"In the Money Option\"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the \"Effective Time\")"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an \"Out of the Money Option\"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement (\"CVR Agreement\") on or prior to the fifth anniversary of the Effective Time (each such date, a \"Valuation Point\"),"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. (\"Parent\") and Sapphire Acquisition Corp. (\"Purchaser\"), pursuant to which Purchaser was merged with and into Issuer (the \"Merger\"), each option to purchase shares (a \"Company Option\") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the \"Shares\") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the \"Closing Amount\") (each, an \"In the Money Option\"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the \"Effective Time\")"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an \"Out of the Money Option\"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement (\"CVR Agreement\") on or prior to the fifth anniversary of the Effective Time (each such date, a \"Valuation Point\"),"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Shares subject to this option were fully vested immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":34.56,"expiration_date":"2022-04-25","underlying":"Common Stock","underlying_shares":2947},"source":{"system":"sec-edgar","filing":"0001209191-16-148104","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1311596/000120919116148104/doc4.xml","form_type":"4"}},{"id":4567546,"issuer":{"id":181299,"kind":"organization","name":"Tobira Therapeutics, Inc.","symbol":"TBRA"},"owners":[{"id":67397,"kind":"person","name":"Podlesak Dennis","position":1,"cik":"0001314595","reported_name":"Podlesak Dennis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2016-11-03T14:27:02.000Z","date":"2016-11-01","kind":"disposition_to_issuer","acquired":false,"shares":53334,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. (\"Parent\") and Sapphire Acquisition Corp. (\"Purchaser\"), pursuant to which Purchaser was merged with and into Issuer (the \"Merger\"), each option to purchase shares (a \"Company Option\") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the \"Shares\") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the \"Closing Amount\") (each, an \"In the Money Option\"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the \"Effective Time\")"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an \"Out of the Money Option\"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement (\"CVR Agreement\") on or prior to the fifth anniversary of the Effective Time (each such date, a \"Valuation Point\"),"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. (\"Parent\") and Sapphire Acquisition Corp. (\"Purchaser\"), pursuant to which Purchaser was merged with and into Issuer (the \"Merger\"), each option to purchase shares (a \"Company Option\") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the \"Shares\") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the \"Closing Amount\") (each, an \"In the Money Option\"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the \"Effective Time\")"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an \"Out of the Money Option\"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement (\"CVR Agreement\") on or prior to the fifth anniversary of the Effective Time (each such date, a \"Valuation Point\"),"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Shares subject to this option were fully vested immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":7.91,"expiration_date":"2026-01-12","underlying":"Common Stock","underlying_shares":53334},"source":{"system":"sec-edgar","filing":"0001209191-16-148104","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1311596/000120919116148104/doc4.xml","form_type":"4"}},{"id":4567545,"issuer":{"id":181299,"kind":"organization","name":"Tobira Therapeutics, Inc.","symbol":"TBRA"},"owners":[{"id":67397,"kind":"person","name":"Podlesak Dennis","position":1,"cik":"0001314595","reported_name":"Podlesak Dennis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2016-11-03T14:27:02.000Z","date":"2016-11-01","kind":"disposition_to_issuer","acquired":false,"shares":27500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. (\"Parent\") and Sapphire Acquisition Corp. (\"Purchaser\"), pursuant to which Purchaser was merged with and into Issuer (the \"Merger\"), each option to purchase shares (a \"Company Option\") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the \"Shares\") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the \"Closing Amount\") (each, an \"In the Money Option\"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the \"Effective Time\")"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an \"Out of the Money Option\"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement (\"CVR Agreement\") on or prior to the fifth anniversary of the Effective Time (each such date, a \"Valuation Point\"),"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. (\"Parent\") and Sapphire Acquisition Corp. (\"Purchaser\"), pursuant to which Purchaser was merged with and into Issuer (the \"Merger\"), each option to purchase shares (a \"Company Option\") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the \"Shares\") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the \"Closing Amount\") (each, an \"In the Money Option\"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the \"Effective Time\")"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an \"Out of the Money Option\"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement (\"CVR Agreement\") on or prior to the fifth anniversary of the Effective Time (each such date, a \"Valuation Point\"),"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Shares subject to this option were fully vested immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":16.52,"expiration_date":"2025-07-08","underlying":"Common Stock","underlying_shares":27500},"source":{"system":"sec-edgar","filing":"0001209191-16-148104","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1311596/000120919116148104/doc4.xml","form_type":"4"}},{"id":4567544,"issuer":{"id":181299,"kind":"organization","name":"Tobira Therapeutics, Inc.","symbol":"TBRA"},"owners":[{"id":67397,"kind":"person","name":"Podlesak Dennis","position":1,"cik":"0001314595","reported_name":"Podlesak Dennis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2016-11-03T14:27:02.000Z","date":"2016-11-01","kind":"disposition_to_issuer","acquired":false,"shares":1071,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. (\"Parent\") and Sapphire Acquisition Corp. (\"Purchaser\"), pursuant to which Purchaser was merged with and into Issuer (the \"Merger\"), each option to purchase shares (a \"Company Option\") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the \"Shares\") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the \"Closing Amount\") (each, an \"In the Money Option\"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the \"Effective Time\")"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an \"Out of the Money Option\"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement (\"CVR Agreement\") on or prior to the fifth anniversary of the Effective Time (each such date, a \"Valuation Point\"),"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. (\"Parent\") and Sapphire Acquisition Corp. (\"Purchaser\"), pursuant to which Purchaser was merged with and into Issuer (the \"Merger\"), each option to purchase shares (a \"Company Option\") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the \"Shares\") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the \"Closing Amount\") (each, an \"In the Money Option\"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the \"Effective Time\")"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an \"Out of the Money Option\"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement (\"CVR Agreement\") on or prior to the fifth anniversary of the Effective Time (each such date, a \"Valuation Point\"),"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Shares subject to this option were fully vested immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":42.93,"expiration_date":"2023-12-31","underlying":"Common Stock","underlying_shares":1071},"source":{"system":"sec-edgar","filing":"0001209191-16-148104","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1311596/000120919116148104/doc4.xml","form_type":"4"}},{"id":4567543,"issuer":{"id":181299,"kind":"organization","name":"Tobira Therapeutics, Inc.","symbol":"TBRA"},"owners":[{"id":67397,"kind":"person","name":"Podlesak Dennis","position":1,"cik":"0001314595","reported_name":"Podlesak Dennis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2016-11-03T14:27:02.000Z","date":"2016-11-01","kind":"disposition_to_issuer","acquired":false,"shares":40733,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. (\"Parent\") and Sapphire Acquisition Corp. (\"Purchaser\"), pursuant to which Purchaser was merged with and into Issuer (the \"Merger\"), each option to purchase shares (a \"Company Option\") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the \"Shares\") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the \"Closing Amount\") (each, an \"In the Money Option\"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the \"Effective Time\")"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an \"Out of the Money Option\"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement (\"CVR Agreement\") on or prior to the fifth anniversary of the Effective Time (each such date, a \"Valuation Point\"),"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. (\"Parent\") and Sapphire Acquisition Corp. (\"Purchaser\"), pursuant to which Purchaser was merged with and into Issuer (the \"Merger\"), each option to purchase shares (a \"Company Option\") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the \"Shares\") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the \"Closing Amount\") (each, an \"In the Money Option\"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the \"Effective Time\")"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an \"Out of the Money Option\"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement (\"CVR Agreement\") on or prior to the fifth anniversary of the Effective Time (each such date, a \"Valuation Point\"),"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Shares subject to this option were fully vested immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":36,"expiration_date":"2023-08-26","underlying":"Common Stock","underlying_shares":40733},"source":{"system":"sec-edgar","filing":"0001209191-16-148104","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1311596/000120919116148104/doc4.xml","form_type":"4"}},{"id":4567542,"issuer":{"id":181299,"kind":"organization","name":"Tobira Therapeutics, Inc.","symbol":"TBRA"},"owners":[{"id":67397,"kind":"person","name":"Podlesak Dennis","position":1,"cik":"0001314595","reported_name":"Podlesak Dennis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2016-11-03T14:27:02.000Z","date":"2016-11-01","kind":"disposition_to_issuer","acquired":false,"shares":10253,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. (\"Parent\") and Sapphire Acquisition Corp. (\"Purchaser\"), pursuant to which Purchaser was merged with and into Issuer (the \"Merger\"), each option to purchase shares (a \"Company Option\") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the \"Shares\") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the \"Closing Amount\") (each, an \"In the Money Option\"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the \"Effective Time\")"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an \"Out of the Money Option\"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement (\"CVR Agreement\") on or prior to the fifth anniversary of the Effective Time (each such date, a \"Valuation Point\"),"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. (\"Parent\") and Sapphire Acquisition Corp. (\"Purchaser\"), pursuant to which Purchaser was merged with and into Issuer (the \"Merger\"), each option to purchase shares (a \"Company Option\") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the \"Shares\") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the \"Closing Amount\") (each, an \"In the Money Option\"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the \"Effective Time\")"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an \"Out of the Money Option\"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement (\"CVR Agreement\") on or prior to the fifth anniversary of the Effective Time (each such date, a \"Valuation Point\"),"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Shares subject to this option were fully vested immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":40.59,"expiration_date":"2020-04-30","underlying":"Common Stock","underlying_shares":10253},"source":{"system":"sec-edgar","filing":"0001209191-16-148104","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1311596/000120919116148104/doc4.xml","form_type":"4"}},{"id":4567541,"issuer":{"id":181299,"kind":"organization","name":"Tobira Therapeutics, Inc.","symbol":"TBRA"},"owners":[{"id":67397,"kind":"person","name":"Podlesak Dennis","position":1,"cik":"0001314595","reported_name":"Podlesak Dennis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2016-11-03T14:27:02.000Z","date":"2016-11-01","kind":"disposition_to_issuer","acquired":false,"shares":232,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. (\"Parent\") and Sapphire Acquisition Corp. (\"Purchaser\"), pursuant to which Purchaser was merged with and into Issuer (the \"Merger\"), each option to purchase shares (a \"Company Option\") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the \"Shares\") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the \"Closing Amount\") (each, an \"In the Money Option\"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the \"Effective Time\")"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an \"Out of the Money Option\"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement (\"CVR Agreement\") on or prior to the fifth anniversary of the Effective Time (each such date, a \"Valuation Point\"),"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. (\"Parent\") and Sapphire Acquisition Corp. (\"Purchaser\"), pursuant to which Purchaser was merged with and into Issuer (the \"Merger\"), each option to purchase shares (a \"Company Option\") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the \"Shares\") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the \"Closing Amount\") (each, an \"In the Money Option\"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the \"Effective Time\")"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an \"Out of the Money Option\"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement (\"CVR Agreement\") on or prior to the fifth anniversary of the Effective Time (each such date, a \"Valuation Point\"),"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Shares subject to this option were fully vested immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":105.21,"expiration_date":"2018-12-08","underlying":"Common Stock","underlying_shares":232},"source":{"system":"sec-edgar","filing":"0001209191-16-148104","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1311596/000120919116148104/doc4.xml","form_type":"4"}},{"id":4567540,"issuer":{"id":181299,"kind":"organization","name":"Tobira Therapeutics, Inc.","symbol":"TBRA"},"owners":[{"id":67397,"kind":"person","name":"Podlesak Dennis","position":1,"cik":"0001314595","reported_name":"Podlesak Dennis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2016-11-03T14:27:02.000Z","date":"2016-11-01","kind":"disposition_to_issuer","acquired":false,"shares":9314,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. (\"Parent\") and Sapphire Acquisition Corp. (\"Purchaser\"), pursuant to which Purchaser was merged with and into Issuer (the \"Merger\"), each option to purchase shares (a \"Company Option\") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the \"Shares\") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the \"Closing Amount\") (each, an \"In the Money Option\"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the \"Effective Time\")"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an \"Out of the Money Option\"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement (\"CVR Agreement\") on or prior to the fifth anniversary of the Effective Time (each such date, a \"Valuation Point\"),"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. (\"Parent\") and Sapphire Acquisition Corp. (\"Purchaser\"), pursuant to which Purchaser was merged with and into Issuer (the \"Merger\"), each option to purchase shares (a \"Company Option\") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the \"Shares\") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the \"Closing Amount\") (each, an \"In the Money Option\"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the \"Effective Time\")"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an \"Out of the Money Option\"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement (\"CVR Agreement\") on or prior to the fifth anniversary of the Effective Time (each such date, a \"Valuation Point\"),"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Shares subject to this option were fully vested immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":112.77,"expiration_date":"2018-08-01","underlying":"Common Stock","underlying_shares":9314},"source":{"system":"sec-edgar","filing":"0001209191-16-148104","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1311596/000120919116148104/doc4.xml","form_type":"4"}},{"id":4567539,"issuer":{"id":181299,"kind":"organization","name":"Tobira Therapeutics, Inc.","symbol":"TBRA"},"owners":[{"id":67397,"kind":"person","name":"Podlesak Dennis","position":1,"cik":"0001314595","reported_name":"Podlesak Dennis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2016-11-03T14:27:02.000Z","date":"2016-11-01","kind":"disposition_to_issuer","acquired":false,"shares":232,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. (\"Parent\") and Sapphire Acquisition Corp. (\"Purchaser\"), pursuant to which Purchaser was merged with and into Issuer (the \"Merger\"), each option to purchase shares (a \"Company Option\") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the \"Shares\") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the \"Closing Amount\") (each, an \"In the Money Option\"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the \"Effective Time\")"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an \"Out of the Money Option\"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement (\"CVR Agreement\") on or prior to the fifth anniversary of the Effective Time (each such date, a \"Valuation Point\"),"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. (\"Parent\") and Sapphire Acquisition Corp. (\"Purchaser\"), pursuant to which Purchaser was merged with and into Issuer (the \"Merger\"), each option to purchase shares (a \"Company Option\") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the \"Shares\") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the \"Closing Amount\") (each, an \"In the Money Option\"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the \"Effective Time\")"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an \"Out of the Money Option\"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement (\"CVR Agreement\") on or prior to the fifth anniversary of the Effective Time (each such date, a \"Valuation Point\"),"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Shares subject to this option were fully vested immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":112.77,"expiration_date":"2018-02-13","underlying":"Common Stock","underlying_shares":232},"source":{"system":"sec-edgar","filing":"0001209191-16-148104","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1311596/000120919116148104/doc4.xml","form_type":"4"}},{"id":4569278,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":67397,"kind":"person","name":"Podlesak Dennis","position":1,"cik":"0001314595","reported_name":"Podlesak Dennis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2016-11-02T17:25:28.000Z","date":"2016-10-31","kind":"grant","acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One hundred percent (100%) of the total number of shares underlying the option shall vest on October 31, 2017, subject to the reporting person's continuous service through the vesting date."}],"balance_after":8000,"derivative":{"exercise_price":11.81,"expiration_date":"2026-10-31","underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001562180-16-003354","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314595/000156218016003354/primarydocument.xml","form_type":"4"}}]}